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Abstract
Cancer has been considered as the most cause of death in world. Employing of 
nanocarriers as drug delivery systems provide a platform for delivering drugs with 
increasing the anti-cancer efficacy, enhancing bioavailability of drugs, reducing 
side effects, enhancing the circulation half-life of drugs, improving the distribution 
of drugs and overcoming drug resistance. A number of nanocarriers have been 
studied as drug delivery systems for improving the treatment of cancer includ-
ing liposomes, micelle, polymeric nanoparticles, carbon nanotubes, dendrimers, 
solid lipid nanoparticle (SLN) and nanostructure lipid carrier (NLC). In order to 
enhance recognition and internalization of nanocarriers by the target tissues, their 
surfaces can be modified with targeting ligands such as integrins, transferrin, folic 
acid, polysaccharides and antibodies. In this chapter, we are going to introduce 
the targeted nanocarriers for improving the cytotoxic action of drugs with further 
attempt of decreasing dose to achieve higher anticancer activity. Targeted nanocar-
riers would provide a promising therapeutic approach for cancer.
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1. Introduction
Colon cancer is one of the most commonly causing death in the world [1]. The 
conventional chemotherapy for colon cancer has a poor efficacy due to side effects 
on normal cells [2, 3]. Moreover, development of multidrug resistance (MDR) remains 
a major obstacle in the cancer treatment [4]. Using of nanocarriers as drug delivery 
systems provide a platform for delivering of drugs with increasing the anti-cancer 
efficacy, reducing side effects, improving therapeutic index, increasing the solubility 
of drugs, increasing bioavailability of drugs, enhancing the circulation half-life of 
drugs, improving the distribution of drugs and overcoming drug resistance [5, 6].
A number of nanocarriers have been employed as drug delivery systems for 
improving cancer treatment including dendrimer [7], chitosan [8], liposome [4], 
polymeric NPs [9], micelle [10] and exosomes [11]. Decorated nanocarriers with 
targeted ligands can identify receptors on cell surface which lead to enhance cellular 
uptake, reduce adverse effects and provide effective release of drugs [12, 13].
2. Nanocarries for colon cancer drug delivery
Sodium alginate, as natural polysaccharide is widely considered as a polymer 
for drug delivery due to hydrophilic, biodegradability, biocompatibility and 
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negatively charged. Stable micelles of sodium alginate-curcumin bioconjugate were 
developed for anti-cancer applications. Sodium alginate-curcumin bioconjugate 
rapidly internalized in colon cancer cells; however, normal cells were less sensitive 
to this bioconjugate. Moreover, these micelles did not induce hemolysis and red cells 
aggregation [10].
Dendrimers are widely considered as nanocarrier for drug delivery due to 
biocompatibility, high drug loading and high surface functionality [7]. PAMAM G5 
dendrimers encapsulated with curcumin and gold NPs (AuNPs) and decorated with 
MUC-1 aptamer were developed for targeted delivery to the colon cancer. AuNPs 
improve the contrast and resolution in the computed tomography (CT). MUC-1 
receptors are overexpressed in the colorectal cancer; therefore, they can be con-
sidered as target for active targeting drug delivery. Targeted PAMAM dendrimers 
exhibited higher cellular cytotoxicity than non-targeted nanocarriers due to the 
higher affinity between MUC1 aptamer and MUC-1 receptor in cancer cells which 
increases the internalization of nanocarriers through receptor-mediated endocyto-
sis. In vivo studies also illustrated the capability of targeted dendrimer as an effec-
tive theranostic system for colon cancer [13].
Employing of pH-controlled drug delivery systems lead to release of drug under 
acidic condition and not under neutral condition. CuS@Cu2S@Au nanoparticles 
(NPs), as a pH-sensitive carrier developed for delivery of doxorubicin (DOX) to 
colon cancer cells. The drug loaded NPs exhibited pH sensitive release and higher 
toxicity than free drug on cancer cells. Furthermore, these NPs showed good 
biocompatibility which make them as promising carrier for drug delivery [5].
Chitosan (CS) as biocompatible polymer is mostly considered as drug delivery 
system due to low toxicity, low immunogenicity, bioadhesion and biodegradability 
[8]. In addition, CS increases the permeability of drugs by regulating the tightness 
between cells [2]. CS NPs were prepared for oral co-delivery of 5-Aminolevulinic 
acid (5-ALA) and photothermal agent (IR780). Results showed that co-delivery 
system increased photodynamic effects against colon cancer cells via enhancing 
oxidative stress, ROS, superoxide and 1O2 production [14].
Luteolin is found in numerous plants that is showed remarkable anti-cancer activ-
ity against skin, breast, liver, prostate and colon cancer. However, its clinical applica-
tion is limited due to poor solubility and low bioavailability. A liposomal formulation 
was designed for improving the anti-tumor activity of luteolin. Liposomal luteolin 
significantly displayed anti-cancer activity against colon cancer cells than free luteolin 
in vitro and in vivo. These findings indicated that liposome formulation improved sol-
ubility and bioavailability of luteolin [15]. Mannose receptors are overexpressed in the 
drug resistant human colon tumor cell lines. Dihydroartemisinin (DHA, a derivative 
of artemisinin) and DOX were co-loaded into mannosylated liposomes for targeted 
delivery to colon cancer cells. These targeted liposomes increased the accumulation 
of both drugs in cancer cells which led to inhibit the growth of cancer cells through 
enhancing apoptosis, low expression of Bcl-xl and induction of autophagy [4].
5-Fluorouracil (5FU) has been commonly used for treatment of colon cancer. 
However, its medical application is restricted due to multidrug resistance, short half-
life, side effects and low therapeutic index [16, 17]. Folic acid-decorated liposomal 
drug delivery system was designed for tumor targeting of 5FU. Targeted liposomes 
displayed higher cellular uptake and more activated apoptotic pathway than free 
drug on cancer cells. Results of hemolysis assay indicated the blood biocompatibil-
ity of the liposomes. Furthermore, folate targeted liposomes exhibited better tumor 
inhibition than free drug [18, 19]. Transferrin targeted liposomal 5FU also triggered 
apoptosis through mitochondria signaling pathway in cancer cells [20].
Cell differentiation 44 (CD44) is also frequently overexpressed on colon cancer 
cells. CD44 is the major receptor of hyaluronic acid (HA) in cancer cells. A smart 
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micelle formulation was prepared using tocopherol succinate (TOS) conjugated 
HA by redox-responsive disulfide bond as a linker. According to the results, the 
micelle could specifically attach to CD44 receptors overexpressed tumor cells 
and responded selectively to high level of glutathione (GSH) in cells which led to 
inducing disulfide bond breakage and the release of paclitaxel (PTX) and triggered 
apoptosis in cancer cells [21].
A biocompatible pH-sensitive copolymer methoxy poly (ethylene glycol)-b-
poly[(hydroxypropyl methacrylamide)-g-α-tocopheryl succinate-g-histidine)] 
(PTH) was synthesized for co-delivery of DOX and α-TOS. Results of in vivo bio-
distribution showed that micelles considerably accumulated in the cancer tissues. 
Moreover, these formulations exhibited higher cytotoxicity on cancer cells than 
normal cells [22].
PLGA, a synthetic copolymer is widely employed as nanocarrier for drug 
delivery system due to biodegradable, biocompatible and non-immunogenic [23]. 
DOTAP-PLGA hybrid NPs were prepared for delivery of 17-allylaminogeldana-
mycin (17AAG) as a HSP90 inhibitor and NPs were decorated with HA. Findings 
showed that internalization of HA-NPs in colon cancer cells was through CD44 
receptor mediated endocytosis. HA-NPs-17AAG induced apoptosis more than free 
17AAG in cancer cells. Additionally, HA-NPs-17AAG significantly inhibited tumor 
growth than free 17AAG in mice [12]. Poly (3-hydroxybutyrate-co-3-hydroxyval-
erate acid) (PHBV)/PLGA NPs were developed for co-delivery of 5FU and 
oxaliplatin for colon cancer treatment. Co-loaded NPs showed significantly higher 
cytotoxicity and anti-tumor efficiency compared to free drugs combination, 
indicating that PHBV/PLGA NPs can be employed as a platform for co-delivery of 
5FU and oxaliplatin [23].
Nanogels are nanosized particles that are formed by chemically or physically 
crosslinked polymer networks [24]. Folic acid functionalized amylopectin-albumin 
core-shell nanogels were designed for improving colon cancer cell targeted delivery 
of curcumin. The curcumin loaded in nanogels exhibited stability against physi-
ological degradation and efficiently triggered apoptosis than free curcumin in 
HT29 cells.
Exosomes are natural membrane vesicles that are secreted into the extracel-
lular environment and can be exploited as drug delivery. Exosomes contain 
bioactive molecules such as lipids, DNA, mRNAs and proteins [11]. Engineered 
exosomes were designed for co-delivery of 5FU and miR-21i (miR-21 inhibi-
tor oligonucleotide) to colon cancer cells. The engineered exosome efficiently 
facilitated cellular uptake of drugs and significantly inhibited miR-21 expression 
in 5FU resistant colon cell lines and increased apoptosis. Moreover, systematic 
administration of 5FU and miR-21i encapsulated exosomes significantly showed 
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